UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 59 filers reported holding UNIQURE NV in Q2 2016. The put-call ratio across all filers is 8.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,683,000 | +33.4% | 175,307 | -14.0% | 1.04% | +16.0% |
| Q2 2017 | $1,262,000 | +7.0% | 203,907 | 0.0% | 0.90% | -9.6% |
| Q1 2017 | $1,179,000 | +3.2% | 203,907 | 0.0% | 1.00% | -0.6% |
| Q4 2016 | $1,142,000 | -26.8% | 203,907 | 0.0% | 1.00% | -7.7% |
| Q3 2016 | $1,560,000 | +33.2% | 203,907 | +28.3% | 1.09% | +17.1% |
| Q2 2016 | $1,171,000 | -38.0% | 158,907 | 0.0% | 0.93% | -43.0% |
| Q1 2016 | $1,888,000 | +226.1% | 158,907 | +354.0% | 1.63% | +215.7% |
| Q4 2015 | $579,000 | -19.1% | 35,000 | 0.0% | 0.52% | -27.3% |
| Q3 2015 | $716,000 | -33.7% | 35,000 | -12.5% | 0.71% | -22.2% |
| Q2 2015 | $1,080,000 | +47.9% | 40,000 | +33.3% | 0.91% | +63.0% |
| Q1 2015 | $730,000 | +24.4% | 30,000 | -24.3% | 0.56% | +20.7% |
| Q4 2014 | $587,000 | +98.3% | 39,656 | +23.9% | 0.46% | +55.2% |
| Q3 2014 | $296,000 | – | 32,000 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |